ArticleBMC cancer2026
Multimodal prehabilitation management within the framework of enhanced recovery after surgery in patients undergoing lung cancer surgery: a scoping review.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundWithin the Enhanced Recovery After Surgery (ERAS) framework, multimodal prehabilitation has emerged as a pivotal strategy to enhance outcomes for patients undergoing lung cancer surgery. Despite its growing recognition, there is a lack of a comprehensive synthesis of the key components and delivery models of multimodal prehabilitation. This scoping review aims to systematically explore the current landscape of multimodal prehabilitation for lung cancer surgery patients, offering a thorough evidence-based framework to guide its optimal clinical implementation and inform future research directions.
methodsFollowing a standard scoping review methodology, we conducted a comprehensive search of major English and Chinese databases (including PubMed, EBSCO, Web of Science, Cochrane Library, CNKI, Wanfang, VIP, and CBM) from their inception to June 30, 2025. Two researchers independently extracted and synthesized data from the included studies.
resultsThe review identified 35 studies, including 22 randomized controlled trials. Multimodal protocols varied in composition, ranging from dual-modal (n = 18) to quadruple-modal (n = 5) approaches. Core components consistently included exercise therapy and pulmonary rehabilitation (n = 34 each), frequently supplemented by psychosocial (n = 20) and nutritional (n = 18) support.
conclusionMultimodal prehabilitation is validated as a critical component of the ERAS pathway in lung cancer surgery, effectively enhancing functional recovery. However, the implementation is challenged by the time-sensitive nature of cancer treatment. Therefore, future care models must pivot toward personalized, home-based digital interventions that can ensure adherence and efficacy within the constrained preoperative window. Moving forward, standardizing these “short-course” protocols will be essential to optimizing both surgical safety and long-term quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.